Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...
BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...
BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...
Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
GlobalData on MSN7d
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerThe US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
BofA analyst David Li upgraded BeiGene (ONC) to Buy from Neutral with a price target of $320, up from $207. The firm raised its revenue ...
24/7 Wall St. on MSN12d
The Billionaire Baker Brothers Just Made This Big Biotech Stock MoveIf you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to. According to ...
Full Year 2024 Results Key Financial Results Revenue: US$3.81b (up 55% from FY 2023). Net ...
Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback